Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award
Agilent Technologies (NYSE: A) announced the Altura Ultra Inert HPLC columns, a new product line aimed at biotherapeutics analysis including peptide GLP-1 and oligonucleotide workflows. The release highlights faster conditioning, improved peak shape, enhanced sensitivity, and a fully inert sample flow path designed for demanding QC and development labs.
Agilent claims up to 2x sensitivity, 3x signal-to-noise ratio, and, when paired with the Agilent 1290 Infinity III Bio LC, up to 30x higher peak area; an external test cited a ~30% sensitivity increase and reduced peak tailing on acidic peptides.
Agilent Technologies (NYSE: A) ha annunciato le colonne Altura Ultra Inert HPLC, una nuova linea di prodotti mirata all'analisi dei bioterapeutici, inclusi flussi di lavoro per peptide GLP-1 e oligonucleotidi. Il comunicato evidenzia una messa a punto più rapida, una forma di picco migliorata, una sensibilità aumentata e un percorso di flusso del campione completamente inerte, progettato per laboratori di QC e di sviluppo particolarmente esigenti.
Agilent afferma fino a 2x di sensibilità, 3x rapporto segnale-rumore e, quando abbinato all'Agilent 1290 Infinity III Bio LC, fino a 30x maggiore area di picco; un test esterno riporta un incremento di sensibilità di ~30% e una riduzione tailing di picchi su peptidi acidi.
Agilent Technologies (NYSE: A) anunció las columnas Altura Ultra Inert HPLC, una nueva línea de productos destinada al análisis de bio-terapéuticos que incluye flujos de trabajo para GLP-1 y oligonucleótidos. El comunicado destaca una condensación más rápida, una mejor forma de picos, mayor sensibilidad y un camino de flujo de muestra totalmente inerte diseñado para laboratorios exigentes de QC y desarrollo.
Agilent afirma hasta 2x de sensibilidad, 3x relación señal-ruido y, cuando se combina con el Agilent 1290 Infinity III Bio LC, hasta 30x mayor área de pico; una prueba externa citó un ~30% incremento de sensibilidad y reducción del tailing de picos en péptidos ácidos.
Agilent Technologies (NYSE: A)는 GLP-1 펩타이드 및 올리고뉴클레오타이드 워크플로를 포함한 생물약품 분석을 목표로 하는 새로운 제품군인 Altura Ultra Inert HPLC 컬럼을 발표했습니다. 이 발표는 더 빠른 컨디셔닝, 향상된 피크 모양, 향상된 민감도, 그리고 까다로운 QC 및 개발 연구소를 위해 설계된 완전히 비활성 시료 흐름 경로를 강조합니다.
Agilent는 최대 2배 민감도, 3배 신호대잡음비, 그리고 Agilent 1290 Infinity III Bio LC와 페어링될 때 최대 30배 더 큰 피크 면적을 약속합니다; 외부 테스트에서는 약 30% 민감도 증가와 산성 펩타이드에서 피크 테일링 감소를 언급했습니다.
Agilent Technologies (NYSE: A) a annoncé les colonnes Altura Ultra Inert HPLC, une nouvelle ligne de produits destinée à l'analyse de biothérapeutiques, y compris des workflows pour le GLP-1 et les oligonucléotides. Le communiqué met en avant un conditionnement plus rapide, une meilleure forme des pics, une sensibilité accrue et un cheminement d'échantillon entièrement inerte conçu pour des laboratoires QC et développement exigeants.
Agilent affirme jusqu'à 2x de sensibilité, 3x de rapport signal-sur-bruit, et, lorsqu'il est associé au Agilent 1290 Infinity III Bio LC, jusqu'à 30x une plus grande aire de pic; un test externe a cité une augmentation de sensibilité d'environ 30% et une réduction du tailing des pics sur les peptides acides.
Agilent Technologies (NYSE: A) hat die Altura Ultra Inert HPLC-Säulen angekündigt, eine neue Produktlinie für die Analyse von Biotherapeutika, einschließlich Workflow für GLP-1-Peptide und Oligonukleotide. Die Veröffentlichung hebt schnellere Konditionierung, verbesserte Peak-Form, verbesserte Empfindlichkeit und einen vollständig inertem Probenflussweg hervor, der für anspruchsvolle QC- und Entwicklungs-Labore konzipiert ist.
Agilent behauptet bis zu 2x Empfindlichkeit, 3x Signal-Rausch-Verhältnis und, wenn er mit dem Agilent 1290 Infinity III Bio LC gepaart wird, bis zu 30x größere Peak-Fläche; ein externen Test zitierte eine ca. 30% Empfindlichkeitssteigerung und eine verringerte Peak-Tailung bei sauren Peptiden.
شركة أجيلنت تكنولوجيز (بورصة نيويورك: A) أعلنت عن عمود Altura Ultra Inert HPLC، خط منتج جديد مخصص لتحليل المستحضرات الحيوية بما في ذلك سير عمل للببتيد GLP-1 والأنوال النووية. يسلط البيان الضوء على تكوين أسرع، وشكل الذروة المحسن، وحساسية عالية، ومسار تدفق عينة خامل تماماً مصمم للمختبرات المتطلبة لضبط الجودة والتطوير.
تزعم حتى 2x حساسية، 3x نسبة الإشارة إلى الضوضاء، وعندما يقترن بـ Agilent 1290 Infinity III Bio LC، حتى 30x مساحة الذروة أعلى; وسلط اختبار خارجي الضوء على زيادة الحساسية نحو حوالي 30% وتقليل tailing الذروة في الببتيدات الحمضية.
- Up to 2x sensitivity versus competitor columns
- 3x signal-to-noise ratio improvement claimed versus competitors
- Up to 30x higher peak area when paired with Agilent 1290 Infinity III Bio LC
- ~30% sensitivity increase and reduced peak tailing reported for GLP-1 peptide analysis
- None.
Insights
Agilent launched the Altura Ultra Inert HPLC columns claiming material sensitivity and chromatographic gains for biotherapeutics workflows.
Agilent expands its LC column portfolio with the Altura Ultra Inert line aimed at peptide and oligonucleotide analysis, positioning the product as a higher‑performance stationary phase that reduces analyte-surface interactions and improves peak shape and sensitivity.
The business mechanism is straightforward: better column inertness and chemistry can reduce signal loss and tailing, which directly improves detection limits and assay robustness for challenging analytes such as GLP‑1 peptides and acidic oligonucleotides. The stated performance uplifts — up to
Key dependencies and risks include real‑world reproducibility across customer labs, compatibility with existing workflows, and independent verification of the vendor performance claims. Customer testimonial data (a
Helping Biopharma Labs Reach New Heights in Analytical Performance
The rapidly evolving biopharma market faces unique challenges in the pursuit of innovative biotherapeutics. High-performance columns and lower limits of detection are required for biopharma labs to accelerate the discovery of these peptide- and oligonucleotide-based therapeutics and meet increasingly rigorous regulatory expectations.
Altura HPLC columns unlock the full separation potential of the stationary phase, delivering superior chromatographic performance — faster conditioning, improved peak shape, and enhanced sensitivity — for even the most challenging analytes. Agilent’s in-house expertise in inert coating, exemplified by the proprietary Ultra Inert technology featured in Altura HPLC columns, delivers consistent, robust performance under demanding operating conditions. This innovation is central to Agilent’s long-term strategy for LC column development.
“Customers producing complex therapeutics are under growing pressure to detect and characterize impurities with greater precision,” said David Edwards, vice president and general manager of the Chemistries and Supplies Division at Agilent. “To support their efforts, Agilent developed the Altura line of inert HPLC columns, which demonstrate up to twice the sensitivity and three times the signal-to-noise ratio compared to competitor columns. When paired with the Agilent 1290 Infinity III Bio LC, up to 30 times higher peak area can be obtained. Named after the Spanish word for ‘height,’ Altura reflects our commitment to help customers reach new heights in analytical performance and scientific discovery.”
“The Altura HILIC-Z HPLC column substantially reduced the undesired analyte-surface interactions in the analysis of GLP-1 receptor agonist drug products,” said Piotr Alvarez, senior scientist at RIC Group, in
The Altura line of LC columns further expands Agilent’s broad range of solutions supporting a fully inert sample flow path. A key addition to their inert flow path portfolio, this launch reinforces Agilent’s focus on delivering innovative products to drive the development and production of exceptionally high-quality therapeutics.
About Agilent Technologies
Agilent Technologies Inc., (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of
View source version on businesswire.com: https://www.businesswire.com/news/home/20250929316398/en/
Media Contact
Naomi Goumillout
Agilent Technologies
978-314-1862
naomi.goumillout@agilent.com
Source: Agilent Technologies Inc.
FAQ
What are the key benefits of Agilent Altura Ultra Inert HPLC columns announced on November 19, 2025?
How do Altura columns improve GLP-1 peptide analysis for labs?
Can Altura columns be used with Agilent 1290 Infinity III Bio LC and what is the claimed effect?
Are Altura HPLC columns designed for oligonucleotide therapeutic development?
What proprietary technology do Altura columns use to achieve inertness?
Where do Altura columns fit in Agilent's product portfolio for biopharma labs?
